The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLMC 2020 | New therapeutic options for low-risk MDS
Sangmin Lee, MD, Weill Cornell Medical College, New York City, NY, outlines discusses recently approved treatments for low-risk myelodysplastic syndromes (MDS). He discusses the approval of luspatercept for low-risk MDS patients with the SF3B1 mutation as a result of the Phase III MEDALIST clinical trial (NCT02631070), and the approval of an oral form of the hypomethylating agent decitabine as a result of the Phase III ASCERTAIN trial (NCT03306264). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Disclosures
Consultancy: AstraZeneca, BMS, Jazz, Roche Diagnostics
DSMB membership: Helsinn
